An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202).

ABSTRACT:

Background

Apatinib has been proved to be effective and well tolerated among patients in phase II and III studies. Here, we evaluated the safety and effectiveness of apatinib in advanced gastric cancer patients in a real-world setting.

Methods

This study enrolled advanced gastric cancer patients who had progressed or relapsed despite systemic chemotherapy. The primary outcome was safety and the secondary outcomes included overall survival (OS) and progression-free survival (PFS).

Results

A total of 337 patients were included. In total, 62 (18.4%), 102 (30.3%), and 173 (51.3%) patients received first, second, and third or higher line apatinib therapy, respectively. Grade 3/4 treatment-emergent adverse events (AEs) were infrequent (<5%), with hypertension (6.8%) being t

SUBMITTER: Wang X 

PROVIDER: S-EPMC7082876 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature